Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.
Liu SL, Li XY, Yang JH, Wen DX, Guo SS, Liu LT, Li YF, Luo MJ, Xie SY, Liang YJ, Sun XS, Yang ZC, Lv XF, Luo DH, Li JB, Liu Q, Wang P, Guo L, Mo HY, Sun R, Yang Q, Lan KQ, Jia GD, Li R, Zhao C, Xu RH, Chen QY, Tang LQ, Mai HQ.
Liu SL, et al. Among authors: xie sy.
Lancet Oncol. 2024 Nov 7:S1470-2045(24)00504-7. doi: 10.1016/S1470-2045(24)00504-7. Online ahead of print.
Lancet Oncol. 2024.
PMID: 39522541